Discover
COGT
Cogent Biosciences, Inc.
38.48
1 x 38.27
2 x 49.47
bid
ask
-
0.22
0.57%
2 @ 04:00 PM
39.00 +0.52 (1.35%)
| Ytd | 8.33% | |
| 1y | 432.96% |
38.12
day range
39.40
7.17
52 week range
43.73
| Open | 38.58 | Prev Close | 38.70 | Low | 38.12 | High | 39.40 | Mkt Cap | 6.58B |
| Vol | 2.30M | Avg Vol | 2.34M | EPS | -2.17 | P/E | N/A | Forward P/E | -40.26 |
| Beta | 0.35 | Short Ratio | 5.69 | Inst. Own | 112.30% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-04 | 50-d Avg | 34.72 | 200-d Avg | 32.08 | 1yr Est | 54.25 |
COGT News
benzinga.com
Cogent Biosciences Files New Drug Application To FDA For Bezuclastinib In Advanced Systemic Mastocyt
Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision the
globenewswire.com
Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced
Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective respons
benzinga.com
Cogent Biosciences To Present Preclinical Data From Its Novel JAK2 V617F Mutant-Selective Inhibitor
We're encouraged by the preclinical data from our next-generation JAK2 program being presented a